Improved survival achieved by HIV‐infected patients has complicated their medical care, as increasing numbers of comorbidities have led to polypharmacy and a higher risk of drug–drug interactions. Here, evidence is… Click to show full abstract
Improved survival achieved by HIV‐infected patients has complicated their medical care, as increasing numbers of comorbidities have led to polypharmacy and a higher risk of drug–drug interactions. Here, evidence is provided that weight‐loss drugs should be used with caution in HIV‐infected patients treated with lipophilic antiretroviral drugs because of the risk of virologic failure. This is particularly relevant considering that these agents are available on the market as over‐the‐counter medications, thus escaping the control of the physician.
Journal Title: Obesity
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!